Alexander V Louie1, Suresh Senan2, Pretesh Patel3, Bart S Ferket4, Frank J Lagerwaard2, George B Rodrigues5, Joseph K Salama3, Christopher Kelsey3, David A Palma5, Myriam G Hunink4. 1. The Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands; The Department of Radiation Oncology, London Regional Cancer Program, London, ON, Canada; The Department of Epidemiology, Harvard School of Public Health, Boston, MA. Electronic address: Dr.alexlouie@gmail.com. 2. The Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 3. The Department of Radiation Oncology, Duke University Medical Center, Durham, NC. 4. The Department of Epidemiology, Harvard School of Public Health, Boston, MA; The Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands. 5. The Department of Radiation Oncology, London Regional Cancer Program, London, ON, Canada.
Abstract
BACKGROUND: The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I non-small cell lung cancer (NSCLC) with stereotactic ablative radiotherapy (SABR) in the absence of pathology is growing. In the absence of randomized evidence, the appropriate prior probability threshold of lung cancer of when such a strategy is warranted can be informed using decision analysis. METHODS: A decision tree and Markov model were constructed to evaluate the relative merits of surveillance, a PET scan-directed SABR strategy (without pathology), or a PET scan-biopsy-SABR strategy, when faced with an SPN at different prior probabilities for lung cancer. Diagnostic characteristics, as well as disease, treatment, and toxicity parameters, were extracted from the literature. Deterministic analysis and probabilistic sensitivity analyses were performed to inform the appropriate lung cancer prior probability threshold between treatment strategies. RESULTS: In the reference case analysis, the prior probability threshold between surveillance and PET scan-biopsy-SABR was 17.0%; between PET scan-directed SABR and PET scan-biopsy-SABR, the threshold was 85.0%. The latter finding was confirmed on probabilistic sensitivity analysis (85.2%; 95% CI, 80.0% to 87.2%). This predicted lung cancer prior probability threshold was most sensitive to the diagnostic sensitivity of transthoracic biopsy (range, 77.2% to 94.0%) and the detection rate of false negatives on CT scan surveillance (range, 82.4% to 92.3%). CONCLUSIONS: This model suggests that if there are concerns about morbidity related to biopsy for an SPN, a PET scan-directed SABR strategy is warranted when the prior probability of lung cancer exceeds a point estimate of 85%.
BACKGROUND: The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I non-small cell lung cancer (NSCLC) with stereotactic ablative radiotherapy (SABR) in the absence of pathology is growing. In the absence of randomized evidence, the appropriate prior probability threshold of lung cancer of when such a strategy is warranted can be informed using decision analysis. METHODS: A decision tree and Markov model were constructed to evaluate the relative merits of surveillance, a PET scan-directed SABR strategy (without pathology), or a PET scan-biopsy-SABR strategy, when faced with an SPN at different prior probabilities for lung cancer. Diagnostic characteristics, as well as disease, treatment, and toxicity parameters, were extracted from the literature. Deterministic analysis and probabilistic sensitivity analyses were performed to inform the appropriate lung cancer prior probability threshold between treatment strategies. RESULTS: In the reference case analysis, the prior probability threshold between surveillance and PET scan-biopsy-SABR was 17.0%; between PET scan-directed SABR and PET scan-biopsy-SABR, the threshold was 85.0%. The latter finding was confirmed on probabilistic sensitivity analysis (85.2%; 95% CI, 80.0% to 87.2%). This predicted lung cancer prior probability threshold was most sensitive to the diagnostic sensitivity of transthoracic biopsy (range, 77.2% to 94.0%) and the detection rate of false negatives on CT scan surveillance (range, 82.4% to 92.3%). CONCLUSIONS: This model suggests that if there are concerns about morbidity related to biopsy for an SPN, a PET scan-directed SABR strategy is warranted when the prior probability of lung cancer exceeds a point estimate of 85%.
Authors: Christopher G Slatore; Nanda Horeweg; James R Jett; David E Midthun; Charles A Powell; Renda Soylemez Wiener; Juan P Wisnivesky; Michael K Gould Journal: Am J Respir Crit Care Med Date: 2015-08-15 Impact factor: 21.405
Authors: Guy C Jones; Jason D Kehrer; Jenna Kahn; Bobby N Koneru; Ram Narayan; Tarita O Thomas; Kevin Camphausen; Minesh P Mehta; Aradhana Kaushal Journal: Clin Lung Cancer Date: 2015-04-23 Impact factor: 4.785
Authors: Nichole T Tanner; Alexander Porter; Michael K Gould; Xiao-Jun Li; Anil Vachani; Gerard A Silvestri Journal: Chest Date: 2017-01-20 Impact factor: 9.410
Authors: Carlos Eduardo Cintra Vita Abreu; Paula Pratti Rodrigues Ferreira; Fabio Ynoe de Moraes; Wellington Furtado Pimenta Neves; Rafael Gadia; Heloisa de Andrade Carvalho Journal: J Bras Pneumol Date: 2015 Jul-Aug Impact factor: 2.624
Authors: Franz Zehentmayr; Martin Sprenger; Lukas Rettenbacher; Romana Wass; Peter Porsch; Gerd Fastner; Christian Pirich; Michael Studnicka; Felix Sedlmayer Journal: Thorac Cancer Date: 2019-01-07 Impact factor: 3.500